Abstract
BackgroundObesity has been associated with the response to biologic disease modifying anti-rheumatic drugs (bDMARDs). Obese patients have lower response to anti-TNF drugs than to other cytokine-targeted drugs, such as anti-IL6[1]....
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
